Key result
CD-340-conjugated PLGA nanoparticles containing doxorubicin reduced tumor growth and drastically reduced doxorubicin-related cardiotoxicity in a mouse model of breast cancer.
Why the study?
Targeted nanoparticle delivery using site-specific ligands is needed to minimize the normal-cell cytotoxicity of chemotherapeutics like doxorubicin.
Population
Human breast cancer cell lines and HER2-overexpressing tumor xenograft mouse models
Comparison
CD-340-conjugated DOX-loaded PLGA nanoparticles vs unconjugated nanoparticles or control groups
Design
Preclinical in vitro and in vivo experimental study
Authors
Loading...
Should not yet alter doxorubicin regimens; hypothesis-generating for targeted nanoparticle delivery in oncology.
Targeted delivery of doxorubicin using CD-340-conjugated nanoparticles reduces tumor growth and minimizes doxorubicin-induced cardiotoxicity in a preclinical breast cancer model.
Mondal et al. (2019) studied Breast cancer. CD-340-conjugated PLGA nanoparticles containing doxorubicin vs. Unconjugated nanoparticles and other controls was evaluated on Tumor growth and cardiac toxicity. CD-340-conjugated PLGA nanoparticles containing doxorubicin reduced tumor growth and drastically reduced doxorubicin-related cardiotoxicity in a mouse model of breast cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: